-
Mashup Score: 2Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review - 1 year(s) ago
Organ-sparing combined-modality treatment for muscle-invasive bladder cancer remains underutilized despite high-quality evidence regarding its efficacy, safety, and preservation of quality of life. It may be offered to patients unwilling to undergo radical cystectomy, as well as those unfit for neoadjuvant chemotherapy and surgery. The treatment plan should be tailored to each patient’s…
Source: MDPICategories: Latest Headlines, UrologyTweet
-
Mashup Score: 2Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi - 3 year(s) ago
In this informative presentation from Andrea Necchi, MD, he presents information related to his goal of finding bladder-sparing treatment options for muscle-invasive bladder cancer (MIBC). Dr. Necchi begins his presentation with a discussion on recent immunotherapy studies for MIBC, the Balar, and IMMUNOPRESERVE studies. He presents evidence that both of these trials have displayed a promising…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
#BladderSparing treatment options for muscle-invasive #BladderCancer. @AndreaNecchi @SanRaffaeleMI joins @UroDocAsh @MDAndersonNews for an in-depth discussion on UroToday. #WatchNow > https://t.co/DjTrZLZQIf @MyUniSR https://t.co/LIqK6fXOEo
-
-
Mashup Score: 0
Neoadjuvant cisplatin-based chemotherapy is associated with pathologic complete response (pCR) in muscle-invasive bladder at the time of cystectomy for a proportion of patients with muscle-invasive bladder cancer (MIBC). Patients with a pCR have improved overall survival relative to patients with no pCR. A challenge in the treatment of patients with MIBC is identifying patients that may be able…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
HCRN GU 16-257 a phase 2 trial of gemcitabine, cisplatin, + nivolumab shows promise for #BladderSparing in muscle-invasive #BladderCancer. @MattGalsky @TischCancer joins @CaPsurvivorship @NUFeinbergMed highlighting data presented at #ASCO21. #WatchNow > https://t.co/5lvX7ypFNt https://t.co/iFkVkMExY7
-
-
Mashup Score: 0
In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as #BladderSparing treatment for #MIBC. @ArjunBalarMD @nyulangone joins @CaPsurvivorship @NUFeinbergMed to discuss this multicenter study. #WatchNow > https://t.co/H0GMLm62nS https://t.co/XmvOP4bRoS
-
-
Mashup Score: 7Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi - 3 year(s) ago
In this informative presentation from Andrea Necchi, MD, he presents information related to his goal of finding bladder-sparing treatment options for muscle-invasive bladder cancer (MIBC). Dr. Necchi begins his presentation with a discussion on recent immunotherapy studies for MIBC, the Balar, and IMMUNOPRESERVE studies. He presents evidence that both of these trials have displayed a promising…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
#BladderSparing treatment options for muscle-invasive #BladderCancer. @AndreaNecchi @SanRaffaeleMI joins @UroDocAsh @MDAndersonNews for an in-depth discussion on UroToday. #WatchNow > https://t.co/DjTrZLZQIf @MyUniSR https://t.co/ST0gDdUNuO
-
-
Mashup Score: 2
Neoadjuvant cisplatin-based chemotherapy is associated with pathologic complete response (pCR) in muscle-invasive bladder at the time of cystectomy for a proportion of patients with muscle-invasive bladder cancer (MIBC). Patients with a pCR have improved overall survival relative to patients with no pCR. A challenge in the treatment of patients with MIBC is identifying patients that may be able…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
HCRN GU 16-257 a phase 2 trial of gemcitabine, cisplatin, + nivolumab shows promise for #BladderSparing in muscle-invasive #BladderCancer. @MattGalsky @TischCancer joins @CaPsurvivorship @NUFeinbergMed highlighting data presented at #ASCO21. #WatchNow > https://t.co/5lvX7ypFNt https://t.co/m1fSJdHsAl
-
-
Mashup Score: 1
In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as #BladderSparing treatment for #MIBC. @ArjunBalarMD @nyulangone joins @CaPsurvivorship @NUFeinbergMed to discuss this multicenter study. #WatchNow > https://t.co/H0GMLm62nS https://t.co/Ydj3NmVtNp
-
-
Mashup Score: 2Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi - 3 year(s) ago
In this informative presentation from Andrea Necchi, MD, he presents information related to his goal of finding bladder-sparing treatment options for muscle-invasive bladder cancer (MIBC). Dr. Necchi begins his presentation with a discussion on recent immunotherapy studies for MIBC, the Balar, and IMMUNOPRESERVE studies. He presents evidence that both of these trials have displayed a promising…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
#BladderSparing treatment options for muscle-invasive #BladderCancer. @AndreaNecchi @SanRaffaeleMI joins @UroDocAsh @MDAndersonNews for an in-depth discussion on UroToday. #WatchNow > https://t.co/DjTrZLZQIf @MyUniSR https://t.co/SjXAmw2UPf
-
-
Mashup Score: 0
Neoadjuvant cisplatin-based chemotherapy is associated with pathologic complete response (pCR) in muscle-invasive bladder at the time of cystectomy for a proportion of patients with muscle-invasive bladder cancer (MIBC). Patients with a pCR have improved overall survival relative to patients with no pCR. A challenge in the treatment of patients with MIBC is identifying patients that may be able…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
HCRN GU 16-257 a phase 2 trial of gemcitabine, cisplatin, + nivolumab shows promise for #BladderSparing in muscle-invasive #BladderCancer. @MattGalsky @TischCancer joins @CaPsurvivorship @NUFeinbergMed highlighting data presented at #ASCO21. #WatchNow > https://t.co/5lvX7ypFNt https://t.co/SASZwQUs5P
-
-
Mashup Score: 3
In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as #BladderSparing treatment for #MIBC. @ArjunBalarMD @nyulangone joins @CaPsurvivorship @NUFeinbergMed to discuss this multicenter study. #WatchNow > https://t.co/H0GMLm62nS https://t.co/W5aFBb6Zb0
-
❓How to start #bladdersparing in your patients with muscle-invasive #bladdercancer? ❓Is patient pathway including "best of both worlds" possible? ➡️ We tried to address these issues in our latest #review in @JCM_MDPI https://t.co/7GCTDZu6IG https://t.co/oXoqwUoyMk